Aldevron News: Events

Plasmid DNA Insights: Expanded Focus on CMC in Gene & Cell Therapy Development

Gene and cell therapy developers are contending with the implications of the evolving regulatory environment while trying to progress programs as quickly as possible to address unmet needs and secure first-mover advantage in competitive indications. Regulators are facilitating efforts to truncate development timelines through a series of designations that can expedite programs while also making efforts to implement standardization.

Read More

In the News: Aldevron Expands Manufacturing Capabilities in Madison

On February 10, Aldevron hosted a virtual celebration of its lab facility expansion in Madison.
 
Aldevron produces the raw materials that allow clients to make groundbreaking therapies, and its protein business unit has operated within University Research Park since 2009. The facility’s growth from 8,000 to nearly 30,000 square feet includes a new 3,500-square-foot fermentation suite and will allow the company to expand its projects’ scope and scale.
 
Read the full article from University of Wisconsin-Madison   here.
 
Additionally, Tom Foti, President of Aldevron's Protein Business Unit provided a virtual tour, which you can view below!
Read More

Advancing Direct Enzyme Delivery for Therapeutic Genome Editing In Vivo

Genome editing enzymes such as Cas9 have been successfully employed to target different genetic disorders in model systems, and ex vivo approaches have demonstrated the clinical potential of this technology. However, the challenge of delivering such corrective enzymes in vivo represents a substantial barrier to therapeutic translation.  

Viral vectors—refined during their use in traditional gene therapy—represent the most widely-used delivery platform in preclinical work, and nanoparticles are quickly maturing into a comparably powerful vehicle. Direct delivery of pre-formed CRISPR enzymes has recently emerged as an appealing strategy for enabling therapeutic editing in vivo.  

Read More

In the News: Aldevron to Host Virtual Ribbon Cutting for Madison Site

Aldevron recently announced its upcoming virtual ribbon cutting event, which will take place on Wednesday, February 10 at 12:00 PM CST. Its focus will be the company's investments in key areas, expanding Aldevron's ability to enable clients' breakthroughs in the emerging field of genetic medicine, further impacting patients and achieving the company's mission.

Read More

Aldevron Honored at 2021 State of the State Address for its 40+ COVID-19 Programs

The Joint Session of the State of North Dakota’s 67th Legislative Assembly held its opening sessions earlier this week, and featured Governor Doug Burgum’s 2021 State of the State address. Burgum reflected on the progress and challenges of the past year, calling for bold action and investments in infrastructure and other priorities to position the state for a bright future.

Read More

Webinar Highlights Potential of Researcher-CMO Collaboration in Gene Editing Therapy

As a Project Scientist for the University of California, Los Angeles, Dr. Mark DeWitt has developed a phase 1 GMP-compatible protocol for correcting diseases that cause gene mutations using a CRISPR-Cas9 modular, non-viral gene editing platform. His specific research focuses on a treatment for sickle cell anemia that is more accessible and less costly than a bone marrow transplant—currently, the only way to address the disease. 

Over the past year, DeWitt has partnered with Aldevron and Synthego, industry leaders in CRISPR-Cas9 nucleases and gRNA manufacturing, respectively.

Read More

Aldevron's Antibody Discovery Team Participating at PEGS

Patricia Odermatt, Senior B-cell Scientist with Aldevron’s Antibody business unit, will be presenting at the  PEGS Boston Summit at 11:30 EDT on Monday, August 31. Her presentation,  Rapid Human Antibody Discovery Utilizing Ligand’s OmniRat® Platform and Berkeley Lights’ Beacon® Instrument will show how three antibody discovery platforms are being used together in developing fully human antibodies against SARS-CoV-2 targets. Patricia will be available at the Aldevron digital booth for additional discussions throughout PEGS. The presentation is only available to those registered for PEGS, which you can find here. However, anyone can connect with our Antibody team at any time through our contact form.
Read More